Related Experiment Video
Updated: Aug 7, 2025
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Cardiovascular disease risk prediction in scleroderma
Aliye Çelikkol1, Rıdvan Mercan2, Savaş Güzel1
1Tekirdağ Namık Kemal University, Faculty of Medicine, Department of Medical Biochemistry - Tekirdağ, Turkey.
Insights
Cardiac myosin-binding protein-C and trimethylamine N-oxide show promise as noninvasive biomarkers for predicting cardiovascular disease risk in scleroderma patients. These markers can help distinguish between low and high-moderate risk groups using the Systematic COronary Risk Evaluation 2 model.
Area of Science:
- Cardiology
- Rheumatology
- Biomarker Discovery
Background:
- Cardiovascular disease (CVD) poses a significant risk for patients with scleroderma.
- Accurate CVD risk prediction is crucial for timely intervention and management in scleroderma.
- Current risk assessment models may benefit from novel, noninvasive biomarkers.
Purpose of the Study:
- To investigate the association between cardiac myosin-binding protein-C (cMyC-C), sensitive troponin T (sTnT), and trimethylamine N-oxide (TMAO) with CVD risk in scleroderma.
- To evaluate the utility of these biomarkers in conjunction with the Systematic COronary Risk Evaluation 2 (SCORE 2) model.
Main Methods:
- A cohort of 52 women with scleroderma and 38 healthy controls were assessed.
- Levels of cMyC-C, sTnT, and TMAO were quantified using commercial ELISA kits.
- Patients were categorized into low and high-moderate CVD risk groups based on the SCORE 2 model.
Main Results:
- Scleroderma patients exhibited significantly higher levels of cMyC-C and TMAO compared to controls (p<0.001 for both).
- sTnT levels did not differ significantly between scleroderma patients and controls (p=0.274).
- TMAO and cMyC-C demonstrated good discriminatory ability for high-moderate CVD risk (sensitivity 76% and 75%, specificity 86% and 83%, respectively).
- Elevated TMAO (≥10.28 ng/mL) and cMyC-C (≥8.29 ng/mL) were independently associated with significantly higher SCORE 2 risk (OR: 15.00 and 11.00, respectively).
Conclusions:
- cMyC-C and TMAO are potential noninvasive biomarkers for assessing CVD risk in scleroderma.
- These biomarkers can aid in differentiating between low and high-moderate CVD risk strata within the SCORE 2 framework.
- Further research is warranted to integrate these findings into clinical practice for improved scleroderma patient management.
Objective:
Cardiovascular disease risk prediction in scleroderma is important. In this study of scleroderma patients, the aim was to investigate the relationship between cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide and cardiovascular disease risk with the Systematic COronary Risk Evaluation 2 model of the European Society of Cardiology.
Methods:
Systematic COronary Risk Evaluation 2 risk groups of 38 healthy controls and 52 women with scleroderma were evaluated. Cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide levels were analyzed with commercial ELISA kits.
Results:
In scleroderma patients, cardiac myosin-binding protein-C and trimethylamine N-oxide levels were higher than healthy controls but sensitive troponin T was not (p<0.001, p<0.001, and p=0.274, respectively). Out of 52 patients, 36 (69.2%) were at low risk, and the other 16 (30.8%) patients were at high-moderate risk with the Systematic COronary Risk Evaluation 2 model. At the optimal cutoff values, trimethylamine N-oxide could discriminate high-moderate risk with sensitivity 76%, specificity 86% and cardiac myosin-binding protein-C with sensitivity 75%, specificity 83%. Patients with high trimethylamine N-oxide levels (≥10.28 ng/mL) could predict high-moderate- Systematic COronary Risk Evaluation 2 risk 15 times higher than those with low trimethylamine N-oxide (<10.28 ng/mL) levels (odds ratio [OR]: 15.00, 95%CI 3.585-62.765, p<0.001). Similarly, high cardiac myosin-binding protein-C (≥8.29 ng/mL) levels could predict significantly higher Systematic COronary Risk Evaluation 2 risk than low cardiac myosin-binding protein-C (<8.29 ng/mL) levels (OR: 11.00, 95%CI 2.786-43.430).
Conclusion:
Noninvasive cardiovascular disease risk prediction indicators in scleroderma, cardiac myosin-binding protein-C, and trimethylamine N-oxide could be recommended to distinguish between high-moderate risk and low risk with the Systematic COronary Risk Evaluation 2 model.
More Related Videos
Related Concept Videos
01:30Coronary Artery Disease I: Introduction
01:26Atherosclerosis III: Management
01:26Coronary Artery Disease IV: Preventive Measures
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:23Rheumatic Heart Disease I: Introduction